78 related articles for article (PubMed ID: 16775185)
1. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival.
Hayes VM; Severi G; Southey MC; Padilla EJ; English DR; Hopper JL; Giles GG; Sutherland RL
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1223-5. PubMed ID: 16775185
[TBL] [Abstract][Full Text] [Related]
2. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
[TBL] [Abstract][Full Text] [Related]
3. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
4. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307
[TBL] [Abstract][Full Text] [Related]
5. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study.
Severi G; Hayes VM; Padilla EJ; English DR; Southey MC; Sutherland RL; Hopper JL; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):610-2. PubMed ID: 17372260
[TBL] [Abstract][Full Text] [Related]
6. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
7. Y chromosome haplotypes and prostate cancer in Sweden.
Lindström S; Adami HO; Adolfsson J; Wiklund F
Clin Cancer Res; 2008 Oct; 14(20):6712-6. PubMed ID: 18927315
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer.
Elkins DA; Yokomizo A; Thibodeau SN; J Schaid D; Cunningham JM; Marks A; Christensen E; McDonnell SK; Slager S; J Peterson B; J Jacobsen S; R Cerhan J; L Blute M; J Tindall D; Liu W
Prostate; 2003 Jun; 56(1):30-6. PubMed ID: 12746844
[TBL] [Abstract][Full Text] [Related]
9. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer.
Arsova-Sarafinovska Z; Matevska N; Petrovski D; Banev S; Dzikova S; Georgiev V; Sikole A; Sayal A; Aydin A; Suturkova L; Dimovski AJ
Cell Biochem Funct; 2008 Oct; 26(7):771-7. PubMed ID: 18646267
[TBL] [Abstract][Full Text] [Related]
10. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.
Johansson M; McKay JD; Rinaldi S; Wiklund F; Adami HO; Grönberg H; Kaaks R; Stattin P
Prostate; 2009 Sep; 69(12):1281-91. PubMed ID: 19455605
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor genotypes/haplotypes and prostate cancer risk.
Cicek MS; Liu X; Schumacher FR; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2549-52. PubMed ID: 17164384
[TBL] [Abstract][Full Text] [Related]
12. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
13. Variants in circadian genes and prostate cancer risk: a population-based study in China.
Chu LW; Zhu Y; Yu K; Zheng T; Yu H; Zhang Y; Sesterhenn I; Chokkalingam AP; Danforth KN; Shen MC; Stanczyk FZ; Gao YT; Hsing AW
Prostate Cancer Prostatic Dis; 2008; 11(4):342-8. PubMed ID: 17984998
[TBL] [Abstract][Full Text] [Related]
14. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA
Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659
[TBL] [Abstract][Full Text] [Related]
15. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia.
Hayes VM; Severi G; Eggleton SA; Padilla EJ; Southey MC; Sutherland RL; Hopper JL; Giles GG
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):993-6. PubMed ID: 15824176
[TBL] [Abstract][Full Text] [Related]
16. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
Wang L; McDonnell SK; Slusser JP; Hebbring SJ; Cunningham JM; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Res; 2007 Apr; 67(7):2944-50. PubMed ID: 17409399
[TBL] [Abstract][Full Text] [Related]
17. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
[TBL] [Abstract][Full Text] [Related]
19. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort.
Stevens VL; Rodriguez C; Talbot JT; Pavluck AL; Thun MJ; Calle EE
Prostate; 2008 Sep; 68(12):1336-40. PubMed ID: 18500687
[TBL] [Abstract][Full Text] [Related]
20. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T
Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
